
Elranatamab reduced the risk of disease progression or death vs standard care in patients with R/R myeloma after prior anti-CD38 therapy and lenalidomide.
Brian Hill, MD, reviews the case of a 73-year-old man with mantle cell lymphoma and discusses the latest data and treatment approaches.
Case: A 73-Year-Old Male With Mantle Cell Lymphoma
History
Currently
